Clinical presentation and predictors of survival related to extent of bone metastasis in 900 prostate cancer patients

References

• NPCR, National Prostate Cancer Register. 2014. Available from: http://npcrse/.2014;http://npcr.se/wp-content/uploads/2015/12/20150930_npcr_report_eng_2014.pdf.
   Google Scholar
• Pagliarulo V, Bracarda S, Eisenberger MA, Mottet N, Schroder FH, Sternberg CN, et al. Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol 2012;61:11–25.
   PubMed Web of Science ®Google Scholar
• Aus G, Robinson D, Rosell J, Sandblom G, Varenhorst E, South-East Region Prostate Cancer G. Survival in prostate carcinoma–outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up: results from three countries in the population-based National Prostate Cancer Registry of Sweden. Cancer 2005;103:943–51.
   PubMed Web of Science ®Google Scholar
• Tangen CM, Hussain MH, Higano CS, Eisenberger MA, Small EJ, Wilding G, et al. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol 2012;188:1164–9.
   PubMed Web of Science ®Google Scholar
• Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000;31:578–83.
   PubMed Web of Science ®Google Scholar
• Zafeirakis A. Scoring systems of quantitative bone scanning in prostate cancer: historical overview, current status and future perspectives. Hell J Nucl Med 2014;17:136–44.
   PubMed Web of Science ®Google Scholar
• Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988;61:195–202.
   PubMed Web of Science ®Google Scholar
• Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013;14:149–58.
   PubMed Web of Science ®Google Scholar
• James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, et al. Survival with newly diagnosed metastatic prostate cancer in the “Docetaxel Era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol 2015;67:1028–38.
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373:737–46.
   PubMed Web of Science ®Google Scholar
• Hedlund PO, Ala-Opas M, Brekkan E, Damber JE, Damber L, Hagerman I, et al. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol 2002;36:405–13.
   PubMed Web of Science ®Google Scholar
• Hedlund PO, Damber JE, Hagerman I, Haukaas S, Henriksson P, Iversen P, et al. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol 2008;42:220–9.
   PubMedGoogle Scholar
• Fayers PM. Interpreting quality of life data: population-based reference data for the EORTC QLQ-C30. Eur J Cancer 2001;37:1331–4.
   PubMed Web of Science ®Google Scholar
• Jonler M, Nielsen OS, Groenvold M, Hedlund PO, Damber L, Hedelin H, et al. Quality of life in patients with skeletal metastases of prostate cancer and status prior to start of endocrine therapy: results from the Scandinavian Prostate Cancer Group Study 5. Scand J Urol Nephrol 2005;39:42–8.
   PubMed Web of Science ®Google Scholar
• Glass TR, Tangen CM, Crawford ED, Thompson I. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol 2003;169:164–9.
   PubMed Web of Science ®Google Scholar
• Gravis G, Boher JM, Fizazi K, Joly F, Priou F, Marino P, et al. Prognostic factors for survival in noncastrate metastatic prostate cancer: validation of the glass model and development of a novel simplified prognostic model. Eur Urol 2015;68:196–204.
   PubMed Web of Science ®Google Scholar
• Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419–24.
   PubMed Web of Science ®Google Scholar
• Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339:1036–42.
   PubMed Web of Science ®Google Scholar
• Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013;368:1314–25.
   PubMed Web of Science ®Google Scholar
• Klaff R, Berglund A, Varenhorst E, Hedlund PO, Jonler M, Sandblom G, et al. Clinical characteristics and quality-of-life in patients surviving a decade of prostate cancer with bone metastases. BJU Int 2016;117:904–13.
   PubMed Web of Science ®Google Scholar
• Eton DT, Lepore SJ. Prostate cancer and health-related quality of life: a review of the literature. Psychooncology 2002;11:307–26.
   PubMed Web of Science ®Google Scholar
• Bellardita L, Valdagni R, van den Bergh R, Randsdorp H, Repetto C, Venderbos LD, et al. How does active surveillance for prostate cancer affect quality of life? A systematic review. Eur Urol 2015;67:637–45.
   PubMed Web of Science ®Google Scholar
• Rosenfeld B, Roth AJ, Gandhi S, Penson D. Differences in health-related quality of life of prostate cancer patients based on stage of cancer. Psychooncology 2004;13:800–7.
   PubMed Web of Science ®Google Scholar
• Nakashima J, Ozu C, Nishiyama T, Oya M, Ohigashi T, Asakura H, et al. Prognostic value of alkaline phosphatase flare in patients with metastatic prostate cancer treated with endocrine therapy. Urology 2000;56:843–7.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Denis L, de Voogt H. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group. Eur Urol 1998;33:134–43.
   PubMed Web of Science ®Google Scholar
• Mulders PF, Dijkman GA, Fernandez del Moral P, Theeuwes AG, Debruyne FM. Analysis of prognostic factors in disseminated prostatic cancer. An update. Dutch Southeastern Urological Cooperative Group. Cancer 1990;65:2758–61.
   PubMed Web of Science ®Google Scholar
• Beer TM, Tangen CM, Bland LB, Hussain M, Goldman BH, DeLoughery TG, et al. The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: a multivariate analysis of Southwest Oncology Group Study 8894. Cancer 2006;107:489–96.
   PubMed Web of Science ®Google Scholar
• Corcoran NM, Costello AJ. Interleukin-6: minor player or starring role in the development of hormone-refractory prostate cancer? BJU Int 2003;91:545–53.
   PubMed Web of Science ®Google Scholar
• James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016;387:1163–77.
   PubMed Web of Science ®Google Scholar